Slama T G
Am J Med. 1983 Jan 24;74(1B):70-3. doi: 10.1016/0002-9343(83)90517-x.
Ten patients with disseminated histoplasmosis and seven with progressive cavitary histoplasmosis were treated with ketoconazole, an imidazole derivative that is well absorbed orally and relatively nontoxic. Seven of seven noncompromised hosts with disseminated disease tolerated therapy well and achieved clinical and mycologic cures. Although well tolerated in all three compromised hosts with disseminated disease, none achieved clinical and bacteriologic cures. All patients with progressive cavitary disease tolerated therapy well and six of seven achieved clinical and radiographic cures. Therefore ketoconazole appears safe and effective in the treatment of disseminated or progressive cavitary histoplasmosis in the noncompromised host. In the compromised host with disseminated histoplasmosis, ketoconazole does not appear to be effective and more conventional therapy appears warranted.
十名播散性组织胞浆菌病患者和七名进行性空洞性组织胞浆菌病患者接受了酮康唑治疗，酮康唑是一种咪唑衍生物，口服吸收良好且相对无毒。七名患有播散性疾病的非免疫功能低下宿主对治疗耐受性良好，并实现了临床和真菌学治愈。虽然所有三名患有播散性疾病的免疫功能低下宿主对治疗耐受性良好，但均未实现临床和细菌学治愈。所有进行性空洞性疾病患者对治疗耐受性良好，七名患者中有六名实现了临床和影像学治愈。因此，酮康唑在治疗非免疫功能低下宿主的播散性或进行性空洞性组织胞浆菌病方面似乎是安全有效的。在患有播散性组织胞浆菌病的免疫功能低下宿主中，酮康唑似乎无效，似乎有必要采用更传统的治疗方法。
